Clinical Trials

Validate and evaluate the diagnostic performance of AMH for predictin poor ovarian response at the pre-defined cutoff of 0.93 ng/ml in both serum and lithium heparin plasma.

The purpose of this study is to evaluate change in telomerase activity as a marker of oocyte quality by evaluating correlation with blastocyst embryo development and clinical pregnancy rate.

The purpose of this study is: 

Infertility Cohort - To determine if maternal blood concentrations of Gal-9, IL-4, and VEGF-A, -C, -D at the time of embryo transfer in patients undergoing in vitro fertilization are predictive of the cycle outcome: live birth or no live birth

Spontaneous Conception Cohort - To determine if maternal blood concentrations of Gal-9, IL-4, and VEGF-A, -C, -D early in the first trimester of gestation are predictive of miscarriage or live birth.

The purpose of this study is to compare outcomes between Day 3 and Day 5 embryo transfer (ET) in patients with five or fewer embryos in an in vitro fertilization (IVF) cycle. Information derived from this trial would allow us to maximize the chances of success for these poor-prognosis patients undergoing IVF.